UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
22.98
-1.30 (-5.35%)
At close: Dec 5, 2025, 4:00 PM EST
23.00
+0.02 (0.09%)
After-hours: Dec 5, 2025, 7:23 PM EST
UroGen Pharma Employees
UroGen Pharma had 235 employees as of December 31, 2024. The number of employees increased by 34 or 16.92% compared to the previous year.
Employees
235
Change (1Y)
34
Growth (1Y)
16.92%
Revenue / Employee
$410,706
Profits / Employee
-$700,604
Market Cap
1.08B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
URGN News
- 17 hours ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates - Seeking Alpha
- 10 days ago - UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum - GlobeNewsWire
- 4 weeks ago - UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial - GlobeNewsWire
- 4 weeks ago - UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference - GlobeNewsWire
- 4 weeks ago - UroGen: Expect Rough Patch Before Strong Recovery In 2026 - Seeking Alpha